Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Optherion Inc.

This article was originally published in Start Up

Executive Summary

Based on a growing understanding of the genetics of age-related macular degeneration and its association with the immune system, Optherion is developing a treatment that it hopes may prevent the disease from progressing into its most serious and debilitating 'wet' form.

You may also be interested in...



Venture Eyes Ophthalmology--And Likes What It Sees

Ophthalmology has long been a bright spot for venture investors given the potential market size, health care burden, and high unmet medical need associated with many eye diseases. Based on a recent analysis by Start-Up magazine, there is no sign that trend is diminishing. Using Elsevier's Strategic Transactions database, Start-Up found that private backers have poured nearly $1.8 billion into 58 ophthalmology start-ups since 1999, with the money split nearly 50/50 in terms of device and drug investments. This trend is likely to accelerate as a number of new acquirers emerge to play in what was once a niche area.

Start-Up Previews (07/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Eye Macular Degeneration," features profiles of Acucela, Iconic Therapeutics, MacuCLEAR, Ophthotech, Optherion and Sirion Therapeutics. "Scoping Out Gastroenterology Start-Ups" features profiles of invendo medical, Mauna Kea Technologies and Softscope Medical Technologies. Plus these Start-Ups Across Health Care: Bone Solutions, Cardioxyl Pharmaceuticals, Savara and VasoNova.

Acucela Inc.

Acucela is developing oral compounds that can possibly slow or stop vision loss caused by dry age-related macular degeneration. Its lead candidate is a small-molecule inhibitor of an enzyme called RPE65, known to be involved in the build-up of A2E, a toxic vitamin A by-product that is implicated in AMD.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel